Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders

What if the solution to cell therapy’s biggest cold-chain challenge comes from the biology of Arctic fish?This conversation features Steve Oh, a leader in advanced bioprocessing, whose career has placed him at the intersection of stem cell biology, process engineering, and clinical translation. Steve Oh joins David Brühlmann to share how XT Thrive®—a next-generation cryopreservation solution drawing from nature’s antifreeze proteins—lets cells survive, thrive, and simplify manufacturing from the bench to the clinic.Episode highlights:Biological insights from Arctic fish and their translation into synthetic peptide chemistry for cell preservation (00:23)The effect of ice crystal formation on cellular damage, and how XT Thrive® minimizes this compared to DMSO (05:32)Simplified logistics: reduced risk of contamination, elimination of post-thaw wash steps, and implications for therapy delivery to remote locations (07:23)Applicability beyond single cells—preserving organoids and potential implications for tissue engineering (09:50)The ease of transitioning from DMSO to the new solution in established lab protocols (10:49)Broader industry challenges: maintaining purity, process optimization, and reducing cost of goods in cell therapy manufacturing (12:03)Promising innovations in rapid cell type differentiation and barriers to scaling transformative biotech (12:50)The importance of supporting innovative therapies beyond short-term ROI (14:17)Smart insight:Next-generation cryopreservation solutions address more than just viability—they simplify transport, reduce costs, lower hands-on time, and help ensure therapy reaches patients in remote locations in optimal condition. As Steve Oh observes, these advances are critical for reducing the cost of goods, improving consistency, and enabling truly scalable cell therapy manufacturing.If you’re interested in this topic, check out these episodes, where we explore how Minnesota’s frozen forests inspired a new wave of biotech innovation—transforming how life-saving cells are frozen, stored, and shipped.Episodes 161 - 162: How to Achieve 85%+ Cell Recovery Without DMSO's Toxic Side Effects with Jeffrey AllenThis is Steve’s second appearance on the podcast. You can also catch his earlier conversation with David, where they explored the challenges and opportunities of cell and gene therapy.Episodes 11 - 12: From Lab to Patient: Steve Oh’s Guide to Mastering Cell Therapy Process Development.Connect with Steve Oh:Email: skwohso@gmail.comLinkedIn: www.linkedin.com/in/steve-oh-4946261/Next step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

Arctic fish survive in waters that would freeze most life solid. Not because they tolerate ice, but because their biology prevents crystals from forming in the first place. That same principle, translated into synthetic peptide chemistry, is now showing performance data that DMSO cannot match. Part 2 is where the science becomes practical.Steve Oh spent 22 years at Singapore's A*STAR accumulating 43 patents across stem cell bioprocessing, microcarrier technologies, and serum-free media. He now advises XTherma, where he has been stress-testing their DMSO-free cryopreservation solution across T cells, MSCs, organoids, and beyond. In Part 2, he brings the data.Key topics discussed:How antifreeze protein-inspired peptide chemistry reduces ice crystal size and protects cells during freezing and thawing (00:23)T cell and MSC performance data comparing XT Thrive to DMSO and CryoStor CS10, including a 2.5-fold increase in cell yield on microcarriers post-thaw (02:23-05:00)Why ice crystal formation causes more damage during thawing than freezing, and how XT Thrive addresses this (05:32)Elimination of the post-thaw wash step and what that means for contamination risk and manufacturing simplicity (07:00)Hold time extended to 24 hours and storage performance across 4°C, -80°C, and -196°C (08:01)Applicability beyond single cells: organoids, islets, and potential implications for organ preservation (09:50)How to transition from DMSO to XT Thrive: GMP grade, Drug Master File, same concentration, no protocol overhaul required (10:49)Broader cell therapy challenges: differentiation time, cell population consistency, and cost of goods (12:03)Smart insight:The transition away from DMSO is more accessible than most scientists assume. XT Thrive is GMP-grade, carries a Drug Master File, and is used at the same 5-10% concentration as DMSO, making it a plug-and-play substitution for most cell types. The manufacturing implications go further: no wash step, extended hold times, and storage stability across all standard temperature ranges simplify both production workflows and cold-chain logistics to remote treatment sites.If you’re interested in this topic, check out these episodes, where we explore how Minnesota’s frozen forests inspired a new wave of biotech innovation, transforming how life-saving cells are frozen, stored, and shipped.Episodes 161 - 162: How to Achieve 85%+ Cell Recovery Without DMSO's Toxic Side Effects with Jeffrey AllenThis is Steve’s second appearance on the podcast. You can also catch his earlier conversation with David, where they explored the challenges and opportunities of cell and gene therapy.Episodes 11 - 12: From Lab to Patient: Steve Oh’s Guide to Mastering Cell Therapy Process Development.Connect with Steve Oh:Email: skwohso@gmail.comLinkedIn: www.linkedin.com/in/steve-oh-4946261/Next step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

Why do CDMOs keep building bigger stainless-steel facilities while their margins erode and Asian competitors undercut them on price? And what happens when big pharma decides to stop outsourcing altogether? The business model that sustained the industry for two decades is under pressure from every direction, and for many CDMOs, standing still is no longer a neutral position.In Part 2, Juergen Mairhofer, CEO of enGenes Biotech, shifts from the science to the stakes. Having spent over a decade building a company on licensing proprietary microbial technology rather than selling fermentation capacity, he brings a distinctive vantage point on where the CDMO industry is headed and what it will take to stay relevant.Here are some of the topics discussed:The need for innovation to stay competitive against lower-cost regions, and why capacity-focused business models are running out of road (03:08)How continuous manufacturing creates a competitive edge for CDMOs operating in high-cost regions (05:49)Practical advice for piloting continuous processing, building partnerships, and taking calculated risks before competitors do (06:36)The parallel universe of batch and continuous manufacturing, and how this duality will shape the industry over the next decade (08:24)What scientists need to know before spinning out a technology company: customer focus, cash discipline, and why the team is everything (09:49)Big pharma's return to in-house manufacturing and vertical supply chain integration, and why this creates opportunity for innovation-focused partners (12:12)Smart insight: Technology excellence is necessary but not sufficient. Juergen's closing word was simply "don't be afraid" and it carried weight precisely because it was not a platitude. The companies that will matter in ten years are those that start the hard work of innovation now, before the window closes.If you’re interested in exploring more breakthroughs in continuous bioprocessing and the future of biotech manufacturing, check out these past episodes from the Smart Biotech Scientist Podcast:Episodes 85 - 86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo MorbidelliEpisodes 153 - 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago MatosEpisode 155: From Process Bottlenecks to Seamless Production: How Continuous Bioprocessing Changes EverythingEpisode 156: The Hidden Economics of Continuous Processing That Most Biotech Companies OverlookEpisodes 181 - 182: Innovating Continuous Bioprocessing with Vibrating Membrane Filtration with Jarno RobinEpisodes 209 - 210: From Batch to Continuous: Building Innovation Culture in Conservative Biotech Environments with Irina RamosConnect with Juergen Mairhofer:LinkedIn: www.linkedin.com/in/juergen-mairhofer-ab27a5benGenes Biotech GmbH website: www.engenes.ccNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

What if continuous microbial manufacturing wasn't a pipe dream, but a reality quietly reshaping the foundations of bioprocessing?Meet Juergen Mairhofer, CEO of enGenes Biotech GmbH and a scientist with a rare dual fluency in molecular biology and bioprocess engineering. He's not just optimizing at the margins. He's devised a proprietary E. coli platform that radically stabilizes genetic stability and splits cell growth from protein production. Instead of stretching out fermentation for a few more days, he's running continuous E. coli processes for up to 40 days; something most believed impossible.Here's why this conversation is worth your notebook and a second listen:Why the commodity CDMO model struggles with innovation and how enGenes Biotech's model aligns business incentives with process improvement (02:37)Juergen Mairhofer's early experiences blending molecular biology and bioprocess engineering, and how a "DIY" mentality led to entrepreneurship (04:42)Strategy behind developing a proprietary E. coli strain that decouples protein production from cell growth (10:01)The benefits of continuous manufacturing: running up to 40-day E. coli processes, and how this compares to mammalian (CHO) systems (13:57)Economic and operational advantages: reducing facility footprint, lowering CAPEX/OPEX, and the necessity for innovation in global competition (19:25)How enGenes Biotech integrates upstream and downstream operations for fully end-to-end continuous production (17:50)Specific technical challenges: managing genetic drift, sterility, equipment, and process modeling in continuous systems (21:10)Smart insight: Technology excellence is the entry ticket, but it won't sell itself. The companies that will lead the next decade of bioprocessing are those willing to align their business model with process innovation, not just capacity utilization.If you’re interested in exploring more breakthroughs in continuous bioprocessing and the future of biotech manufacturing, check out these past episodes from the Smart Biotech Scientist Podcast:Episodes 85 - 86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo MorbidelliEpisodes 153 - 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago MatosEpisode 155: From Process Bottlenecks to Seamless Production: How Continuous Bioprocessing Changes EverythingEpisode 156: The Hidden Economics of Continuous Processing That Most Biotech Companies OverlookEpisodes 181 - 182: Innovating Continuous Bioprocessing with Vibrating Membrane Filtration with Jarno RobinEpisodes 209 - 210: From Batch to Continuous: Building Innovation Culture in Conservative Biotech Environments with Irina RamosConnect with Juergen Mairhofer:LinkedIn: www.linkedin.com/in/juergen-mairhofer-ab27a5benGenes Biotech GmbH website: www.engenes.ccNext step:Need fast CMC guidance? → Get rapid CMC decision support hereOne bad CDMO decision can cost you two years and your Series A. If you're navigating tech transfer, CDMO selection, or IND prep, let's talk before it gets expensive. Two slots open this month.Support the show

For many biotech innovators, high-throughput screening platforms promise faster discoveries and streamlined workflows. Yet beneath the surface, the reality is more demanding, requiring hands-on expertise, careful assay design, and a sharp understanding of microbial physiology to avoid mistakes that become expensive to fix downstream.David Brühlmann continues his conversation with Sebastian Blum, Market Development Manager in Europe at Beckman Coulter Life Sciences, who brings a practical, unvarnished perspective to high-throughput screening. Drawing on conversations with startups, pharma, and CDMOs, Sebastian digs into what separates "push-button" automation myths from hard-won bioprocess mastery. From evaluating technical fit to troubleshooting real-world applications, he advocates for a nuanced approach, one focused on fit-for-purpose tools and critical thinking over technology hype.In this episode, we discuss:Practical advice for startups considering systems like the BioLector XT Microbioreactor, including the need for technical expertise and tailored applications (02:34)Scenarios where the BioLector XT Microbioreactor is the best fit (flexibility, multiple microorganisms, modular upgrades) (04:22)The most common mistakes scientists make with screening technologies, and why specialized personnel are still essential (06:45)How automation, robotics, and AI are shaping the future of early-stage bioprocess development, and why core engineering principles remain vital (08:14)Tips for evaluating screening tool placement in your process and aligning technology with your application needs (11:13)If you're making decisions about high-throughput screening platforms and want to avoid costly missteps before scale-up, this episode delivers the clarity you need.Connect with Sebastian Blum:LinkedIn: www.de.linkedin.com/in/sebastian-blum-76240b3bBeckman Coulter Life Sciences: www.beckman.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

Why do so many promising biotech ideas stall long before they reach the clinic or marketplace? For many, the answer lies hidden in the earliest phase of bioprocess development: upstream processing. It’s where strain selection, media optimization, and culture conditions set the stage for everything that follows. Yet, the smallest missteps here can snowball into expensive roadblocks downstream. This episode of Smart Biotech Scientist Podcast zeros in on why smart screening strategies and the right bioreactor choices early on are the difference between breakthrough and bottleneck.Joining host David Brühlmann is Sebastian Blum, a microbiologist with more than two decades in the life sciences. As Market Development Manager at Beckman Coulter Life Sciences, Sebastian Blum brings firsthand knowledge from collaborating with startups, pharma giants, and CDMOs, bridging theory with the practical realities of modern process development. From commercializing micro-fermentation systems to guiding clients through high-throughput data, his insights come not just from research but real-world applications.Key Topics & Insights:How startups versus large pharma companies differ in process development strategies, including the role of budget, resources, and risk management. (04:27)The importance of designing screening experiments that mirror end-process conditions, and misconceptions around batch versus fed-batch modes. (07:49)Overview of available small-scale bioreactor systems: shake flasks, benchtop reactors, and high-throughput platforms—pros, cons, and ideal use cases. (09:17)Detailed comparison of BioLector XT Microbioreactor, ambr® 15, and ambr® 250 systems, including working volumes, experiment throughput, measurement technology, and cell types suited for each. (13:24)Practical guidance on making the most of high-throughput screening tools and how training, scripting, and collaboration help new users get value from systems like the BioLector XT Microbioreactor. (17:00)This episode offers grounded advice for scientists and founders navigating early-stage bioprocess development, plus a clear look at the technology landscape for microbial screening and optimization. Perfect for those looking to streamline process development and avoid common pitfalls.Connect with Sebastian Blum:LinkedIn: www.de.linkedin.com/in/sebastian-blum-76240b3bBeckman Coulter Life Sciences: www.beckman.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

For years, mammalian cells and microbial systems have dominated the biotech landscape, shaping the economics and access to life-saving biologics. Yet, in countries where capital and infrastructure are limited, those gold-standard systems bring hefty price tags and daunting complexity. The answer isn't bigger bioreactors; it's alternative biomanufacturing approaches, such as molecular farming. Imagine medicines grown like crops, ready for harvest in days, not months.Meet Waranyoo Phoolcharoen, Co-Founder and CTO of Baiya Phytopharm and Professor at Chulalongkorn University in Bangkok, a scientist who didn't settle for the status quo. As the driving force behind the company, she led the charge to cut through process bottlenecks: navigating regulatory hurdles, scaling plant-based vaccine manufacturing to 5 million doses per month, and reshaping the approach to antibody production for oncology and infectious diseases. Her work proved that plants aren't an alternative. They're a platform.Topics discussed include:How plant-based molecular farming compares to traditional microbial and mammalian cell systems (02:44)The flexibility and rapid scalability of using plants for biomanufacturing (05:06)Speeding up process development with transient expression versus transgenic plants (05:45)Regulatory perspectives and the approval process for plant-produced biologics (06:52)An overview of the ongoing oncology and infectious disease antibody pipeline (08:08)Strategic challenges: balancing product development, revenue, and market-ready innovations through subsidiary companies (09:51)Lessons learned from building a GMP facility capable of 5 million doses per month during the pandemic, with supply chain as the biggest bottleneck (12:50)Future innovations in molecular farming and the role of plant platforms in medicine production (14:47)Smart insight:Platform choice matters. If you're struggling with long development timelines or scale-up challenges, it may not always be the molecule. It may be the system you're using. Molecular farming offers a different set of trade-offs: faster development, flexible scaling, and a practical alternative worth considering before defaulting to a single platform.If you’re interested in other unconventional biological platforms reshaping biomanufacturing, don’t miss these episodes exploring emerging production technologies:Episodes 141 - 142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel BardorEpisodes 163 - 164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas SchaafEpisodes 229 - 230: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim CorcoranConnect with Waranyoo Phoolcharoen:Email: Waranyoo.P@baiyaphytopharm.comBaiya Phytopharm website: www.baiyaphytopharm.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

Imagine producing life-saving antibodies or vaccines not in sprawling stainless steel facilities, but in sunlit greenhouses, inside living, breathing plants.Waranyoo Phoolcharoen, Co-Founder and CTO of Baiya Phytopharm and Professor at Chulalongkorn University in Bangkok, leads the charge in molecular farming in Thailand, pioneering a shift from traditional biomanufacturing toward using whole plants as responsive biofactories. With a unique background in both pharmaceutical sciences and plant biotechnology, she has taken her research out of the academic silo and into the world, founding a clinical-stage company determined to make vaccines and therapeutic proteins accessible where they're needed most.In this episode, we cover:Waranyoo Phoolcharoen's personal journey: from an accidental start in plant biotechnology to making a global impact with molecular farming (03:57)The pivotal moment that shifted her focus from publishing papers to translating research into real-world solutions (06:12)The initial steps and uncertainties of co-founding Baiya Phytopharm in Thailand (07:12)How 'the plant of life' philosophy drives their biopharma platform, and why whole plants (not just cell cultures) are used as biofactories (09:56)Key mindset shifts when transitioning from academia to entrepreneurship, including the importance of teamwork and commercial thinking (12:55)Strategies for making impact-driven biotech startups in resource-constrained environments, and why courage and speed matter (15:50)Insights into the biotech and pharmaceutical landscape in Southeast Asia, including opportunities and challenges for innovators (19:27)Smart insight:The most important mindset shift from scientist to entrepreneur isn't technical; it's learning to ask different questions. Not "is this interesting?" but "who will pay for this, and does it make commercial sense?" As Waranyoo puts it, when you have the right question, it leads to the right answer.Stay tuned for Part 2, where we'll explore platform capabilities and Asia's first plant-derived COVID-19 vaccine to enter clinical trials.If you’re interested in other unconventional biological platforms reshaping biomanufacturing, don’t miss these episodes exploring emerging production technologies:Episodes 141 - 142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel BardorEpisodes 163 - 164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas SchaafEpisodes 229 - 230: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim CorcoranConnect with Waranyoo Phoolcharoen:Email: Waranyoo.P@baiyaphytopharm.comBaiya Phytopharm website: www.baiyaphytopharm.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereOne bad CDMO decision can cost you two years and your Series A. If you're navigating tech transfer, CDMO selection, or IND prep, let's talk before it gets expensive. Two slots open this month.Support the show

Picture a new bioprocess automation project: ambitious, expensive, and packed with promise. But after months of development, your team discovers a flaw that could have been caught with a simple mockup and a few sticky notes on a whiteboard. This episode confronts the real cost of skipping discovery, premature automation, and the myth that faster engineering always means faster solutions.Anthony Catacchio, CEO of Product Insight, continues his conversation with David Brühlmann to untangle the realities of automation strategy in biotech. Drawing from years of building robotics for high-stakes labs, Anthony explores why "minimum testable product" consistently outperforms "minimum viable product" when budgets, timelines, and patient outcomes are on the line.Highlights from the episode:When custom robotics development is genuinely justified — and the conditions that determine whether a large-scale automation investment makes sense for your organization (02:59).Tech demos and usability demos: how to test the hardest parts of your system concept in isolation before committing to full development (06:37).Minimum testable product vs. minimum viable product: why rushing to viable in hardware development is a costly mistake, and how controlled pilot deployments generate the learning that actually accelerates your program (07:37).Why testing in the real operating environment — not a simulated lab setting — is the only way to surface the hidden requirements that will determine whether your automation succeeds or fails (08:29).The "go fever" trap: why problems discovered late in development get buried rather than fixed, and how front-loading validation protects both your timeline and your budget (10:16).The single most practical question a biotech scientist can ask to determine whether a process is a genuine automation candidate: how much are you thinking while you do it? (16:02).Where AI and machine learning deliver real value in bioprocess research — and why the more urgent question is not how to automate a process, but how to redesign it to produce better data (17:59).Why capital equipment in biotech labs will need to change fundamentally to collect the volume and quality of data required to make AI-driven insights meaningful (19:01).Smart insight: Automation is not a technology problem, it is a systems development and requirements development problem. The teams that deeply understand their process and environment before touching a line of code or a line of engineering will always outperform those that do not. As Anthony puts it: you need to look at the whole picture.Connect with Anthony Catacchio:LinkedIn: www.linkedin.com/in/anthony-catacchio-b881581bProduct Insight website: www.productinsight.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

Many bioprocess automation projects fail, not because the technology is wrong, but because no one clearly defined the problem before buying the robot.In this episode, David Brühlmann sits down with Anthony Catacchio, CEO of Product Insight, to explore why rigorous system design and honest problem definition matter more than any individual technology, and how industrial robotics expertise translates directly into smarter lab automation.Highlights from the episode:Why biotech's "special case" mindset around automation is costing companies time and money — and what industrial robotics already has figured out (02:45).How Anthony's cross-industry career — from surgical devices to warehouse robotics — shaped a process-first approach to system design (05:05).The automation paradox: how to increase throughput and reduce errors without eliminating the expert human judgment your process depends on (09:13).Vision-guided robotics, AGVs, and quadrupeds: what has genuinely changed in capability and what that means for bioprocess applications (11:21).Human-bot testing: the low-cost validation method that reveals workflow flaws before a single robot is purchased (15:07).The $1M vs. $10K decision: a real case study where the right answer was walking away from automation entirely (15:54).Why talking a client out of an expensive project is sometimes the highest-value service a technical consultant can deliver (17:38).Building long-term credibility by recommending the simplest solution that actually solves the problem (19:24).Smart insight: The most expensive automation mistake happens at the whiteboard, not on the manufacturing floor. Define the problem with surgical precision before you ever evaluate a solution.In Part 2, the conversation continues with a deeper look at building automation systems that deliver practical solutions to bioprocessing challenges without overengineering.Tune in for practical strategies and honest reflections on automation, system design, and the importance of clear problem definition in biotech hardware development.Connect with Anthony Catacchio:LinkedIn: www.linkedin.com/in/anthony-catacchio-b881581bProduct Insight website: www.productinsight.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show